Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
Karyopharm Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 19, 2019
Karyopharm Therapeutics reported fiscal year 2018 executive compensation information on April 19, 2019.
In 2018, five executives at Karyopharm Therapeutics received on average a compensation package of $1.9M, a 14% decrease compared to previous year.
Average pay of disclosed executives at Karyopharm Therapeutics
Anand Varadan, Executive Vice President, Chief Commercial Officer, received $2.3M in total. 85% of Varadan's compensation, or $2M, was in option awards. Varadan also received $25K in bonus, $102K in non-equity incentive plan, $212K in salary, as well as $11K in other compensation.
Michael G. Kauffman, Chief Executive Officer, received a compensation package of $2.3M, which decreased by 14% compared to previous year. 64% of the compensation package, or $1.4M, was in option awards.
Sharon Shacham, Chief Scientific Officer, earned $2.1M in 2018, a 16% decrease compared to previous year.
Christopher B. Primiano, General Counsel, received $1.5M in 2018, which increases by 5% compared to 2017.
Michael Falvey, M.S.M, Chief Financial Officer, earned $1.3M in 2018.
Related executives
Michael Kauffman
Karyopharm Therapeutics
Chief Executive Officer
Michael MSM
Karyopharm Therapeutics
Chief Financial Officer
Sharon Shacham
Karyopharm Therapeutics
Chief Scientific Officer
Christopher Primiano
Karyopharm Therapeutics
General Counsel
Anand Varadan
Karyopharm Therapeutics
Executive Vice President, Chief Commercial Officer
You may also like
Source: SEC filing on April 19, 2019.